# A Study to Evaluate the Tolerance, Pharmacokinetics and Efficacy of TQ-A3334 Tablets

> **NCT04273815** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Chia Tai Tianqing Pharmaceutical Group Co., Ltd.** · enrollment: 40 (estimated)

## Conditions studied

- Non-small Cell Lung Cancer

## Interventions

- **DRUG:** TQ-A3334
- **DRUG:** Anlotinib

## Key facts

- **NCT ID:** NCT04273815
- **Lead sponsor:** Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-07-06
- **Primary completion:** 2021-01-31
- **Final completion:** 2021-01-31
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2020-07-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04273815

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04273815, "A Study to Evaluate the Tolerance, Pharmacokinetics and Efficacy of TQ-A3334 Tablets". Retrieved via AI Analytics 2026-07-08 from https://api.ai-analytics.org/clinical/NCT04273815. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*